The amount of the transaction was not disclosed.
The acquisition aims to expand PCI’s presence in the UK/EU to support global investigational studies of medicinal products by adding packaging, storage and distribution capacity, as well as consultative services for clinical trial supplies.
Led by Fiona Withey, CEO, Biotec supports global projects across a range of temperature conditions including controlled room temperature, 2 – 8°C, -20°C, -40°C, -80°C, and specialization in products requiring -196°C.
The company stores, packages and ships Cold Chain products, and Advanced Therapeutic Medicinal Products (ATMP) including gene therapies, somatic cell therapies (stem cells) and tissue engineered products.
Established in 1997 and led by Bill Mitchell, CEO and President, PCI had acquired Penn Pharma last month, adding pharmaceutical development and contained manufacturing services to its portfolio of Clinical Trial Services, Commercial packaging, and Laboratory services and AndersonBrecon in 2013 from AmerisourceBergen.
PCI now represents 16 facilities across North America and Europe, employing over 2,900 highly trained associates, supporting therapies destined to over 100 countries around the world.
It is principally owned by Frazier Healthcare, with partner investors QIC Global Private Equity, Greenspring Associates and Thomas, McNerney & Partners.